"10.1371_journal.pone.0097149","plos one","2014-05-30T00:00:00Z","Rachael L DiSantostefano; Tim Sampson; Hoa Van Le; David Hinds; Kourtney J Davis; Nawar Diar Bakerly","Worldwide Epidemiology, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America; Salford Royal NHS Foundation Trust and Manchester University, Manchester, United Kingdom","Conceived and designed the experiments: RLD TS HVL DH KJD NDB. Analyzed the data: RLD TS HVL DH. Wrote the paper: RLD TS HVL DH KJD NDB. Data interpretation: RLD HVL DH KJD NDB.","RLD, TS, HVL and KJD are employees of and hold stock in GlaxoSmithKline. DH is a full-time contractor at GlaxoSmithKline. NDB had received unrestricted educational grants from GSK, Novartis and Boehringer Ingelheim, as well as advising GSK and Novartis on various study designs. GSK manufactures inhaled corticosteroid-containing medications including fluticasone propionate, fluticasone propionate/salmeterol in combination, and fluticasone furoate/vilanterol in combination. This study was conducted to evaluate the safety of the ICS-containing medication class in an observational setting in patients with COPD and includes fluticasone propionate-containing medications in the analysis period. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2014","05","Rachael L DiSantostefano","RLDS",6,TRUE,6,NA,4,6,TRUE,TRUE,FALSE,0,NA,FALSE
